The Blueprint for Better Lung Cancer Screening

Originally published on Devex.com

By Devex Partnerships

Listen on Spotify, Apple Podcasts, Soundcloud, YouTube, or search "Devex" in your favorite podcast app.

NORTHAMPTON, MA / ACCESS Newswire / July 8, 2026 / Kentucky has the highest lung cancer rates in the U.S., but it's also becoming a model for how to fight back. Experts behind the QUILS™ system join Devex to discuss early detection, coalition building, and lessons applicable to health systems worldwide.

In this special edition of the This Week in Global Development podcast, produced in partnership with the Bristol Myers Squibb Foundation, Devex cofounder and Executive Vice President Alan Robbins sits down with three architects of Kentucky's transformation in fighting high lung cancer rates: Dr. Jamie Studts, Dr. Jennifer Redmond Knight, and Dr. Timothy Mullett - the team behind the Kentucky LEADS Collaborative and the QUILS™ system.

After a decade of data, the results are clear: earlier diagnoses are being seen in Kentucky, and current efforts are seeking a similar impact in Mississippi and Nevada. But the real story is how these results were achieved. Rather than imposing top-down protocols, QUILS™ works by equipping local community programs with data-informed tools, continuous feedback, and practice support - helping local clinics serve as trusted access points for lung cancer screening in their communities.

The conversation tackles the hardest part of scaling any screening program: human behavior. Lung cancer carries a unique stigma rooted in decades of anti-smoking messaging, and that stigma remains a powerful barrier, discouraging eligible patients from coming forward. The QUILS™ response is to replace shame and fear with empathy and hope, building person-centered care directly into clinical workflows so the burden does not fall on patients alone.

For global health leaders, the implications are clear: The barriers Kentucky faced - rural isolation, underresourced systems, cultural mistrust - are not unique to one region. They exist everywhere. And the infrastructure built to overcome them may be exactly what the world needs.

Watch the full podcast here: Special edition: The blueprint for better lung cancer screening

Find more stories and multimedia from Bristol-Myers Squibb Company at 3blmedia.com.

Contact Info:
Spokesperson: Bristol-Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: info@3blmedia.com

SOURCE: Bristol-Myers Squibb Company



View the original press release on ACCESS Newswire

News Provided by ACCESS Newswire via QuoteMedia

BMY
The Conversation (0)
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974

Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974

Lawsuits have been filed alleging that a number of large corporate employers have offloaded billions of dollars in pension obligations to Athene Annuity and Life Company andor Athene Annuity & Life Assurance Company of New York, subsidiaries of Athene Holding Ltd. (collectively, "Athene") in... Keep Reading...
Bristol Myers Squibb Reports First Quarter Financial Results for 2023

Bristol Myers Squibb Reports First Quarter Financial Results for 2023

Reports First Quarter Revenues of $11.3 Billion Posts First Quarter GAAP Earnings Per Share of $1.07 and Non-GAAP EPS of $2.05; Includes Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income Delivers Strong Revenue Growth of 8% from In-Line... Keep Reading...
Bristol Myers Squibb Announces Leadership Transition Plan

Bristol Myers Squibb Announces Leadership Transition Plan

Giovanni Caforio, MD, Bristol Myers Squibb Chairman and CEO, to Retire as CEO, Effective November 1, 2023; Will Continue as Executive Chairman of the Board Christopher Boerner, PhD, EVP, Chief Commercialization Officer, Appointed EVP, Chief Operating Officer, Effective Immediately; to Succeed... Keep Reading...
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS®  for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

If approved, CAMZYOS would be the first cardiac myosin inhibitor in Europe that specifically targets the source of obstructive HCM Recommendation based on positive Phase 3 EXPLORER-HCM and VALOR-HCM trials demonstrating benefit in patients receiving CAMZYOS versus placebo Bristol Myers Squibb... Keep Reading...
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production

Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production

Libertyville, Illinois facility bolsters long-term viral vector supply with multi-product, in-house viral vector production capabilities Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through... Keep Reading...

Interactive Chart

Latest Press Releases

Related News